Matthew James Walton

Search results

• 2019

  Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

  Walton, M., Sharif, S., Simmonds, M., Claxton, L. & Hodgson, R., 13 Apr 2019, In: PharmacoEconomics. 37, 10, p. 1209-1217 9 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  File